Nervgen Pharma (NGEN) Operating Expenses (2025 - 2026)
Nervgen Pharma's (NGEN) quarterly Operating Expenses came in at $8.8 million in Q2 2026, up 88.86% year-over-year from $4.7 million in Q2 2025, and up 60.55% quarter-over-quarter from $5.5 million in Q1 2026.
Powered by 
Analysis
Nervgen Pharma (NGEN) Operating Expenses (2025 - 2026) Analysis & Trends
Nervgen Pharma (NGEN) has reported Operating Expenses for 2 consecutive years, with $8.8 million the latest figure, recorded in Q2 2026.
- On a quarterly basis, Operating Expenses rose 88.86% year-over-year to $8.8 million in Q2 2026; TTM through Jun 2026 was $23.2 million, a N/A change from a year earlier, with the FY2025 full-year figure at $18.0 million, down 2.2% from the prior year.
- Operating Expenses was $8.8 million for Q2 2026 at Nervgen Pharma, up from $5.5 million in the prior quarter.
- Over five years, Operating Expenses peaked at $8.8 million in Q2 2026 and troughed at $4.2 million in Q1 2025.
Peer Set
Peer Comparison
| # | Company | Market Cap | Enterprise Value | Gross Profit (Qtr) | Opex (Qtr) |
|---|---|---|---|---|---|
| 1 | Amgen | 211.73 Bn | 197.74 Bn | 7.24 Bn | 6.54 Bn |
| 2 | Gilead Sciences | 180.92 Bn | 177.74 Bn | 6.22 Bn | 18.20 Bn |
| 3 | Vertex Pharmaceuticals | 132.16 Bn | 124.30 Bn | 2.84 Bn | 2.09 Bn |
| 4 | Regeneron Pharmaceuticals | 82.89 Bn | 74.90 Bn | 3.93 Bn | 3.00 Bn |
| 5 | Argenx Se | 61.41 Bn | 56.23 Bn | 1.37 Bn | -1.05 Bn |
| 6 | Moderna | 53.99 Bn | 48.85 Bn | 52.00 Mn | 960.00 Mn |
| 7 | Alnylam Pharmaceuticals | 34.48 Bn | 31.18 Bn | 992.69 Mn | 1.06 Bn |
| 8 | Biogen | 31.15 Bn | 29.86 Bn | 1.96 Bn | 2.60 Bn |
| 9 | Roivant Sciences | 30.05 Bn | 30.05 Bn | 1.16 Mn | 367.83 Mn |
| 10 | Nervgen Pharma | 155.15 Mn | 155.15 Mn | - | 8.82 Mn |
Historic Data
Download Data
Historic Data
| Date | Value |
|---|---|
| Jun 30, 2026 | 8.82 Mn |
| Mar 31, 2026 | 5.49 Mn |
| Jun 30, 2025 | 4.67 Mn |
| Mar 31, 2025 | 4.21 Mn |